Clinical Endoscopy (May 2023)

Pancreatic duct lavage cytology combined with a cell-block method for patients with possible pancreatic ductal adenocarcinomas, including pancreatic carcinoma

  • Hiroaki Kusunose,
  • Shinsuke Koshita,
  • Yoshihide Kanno,
  • Takahisa Ogawa,
  • Toshitaka Sakai,
  • Keisuke Yonamine,
  • Kazuaki Miyamoto,
  • Fumisato Kozakai,
  • Hideyuki Anan,
  • Kazuki Endo,
  • Haruka Okano,
  • Masaya Oikawa,
  • Takashi Tsuchiya,
  • Takashi Sawai,
  • Yutaka Noda,
  • Kei Ito

DOI
https://doi.org/10.5946/ce.2022.021
Journal volume & issue
Vol. 56, no. 3
pp. 353 – 366

Abstract

Read online

Background/Aims This study aimed to clarify the efficacy and safety of pancreatic duct lavage cytology combined with a cell-block method (PLC-CB) for possible pancreatic ductal adenocarcinomas (PDACs). Methods This study included 41 patients with suspected PDACs who underwent PLC-CB mainly because they were unfit for undergoing endoscopic ultrasonography-guided fine needle aspiration. A 6-Fr double lumen catheter was mainly used to perform PLC-CB. Final diagnoses were obtained from the findings of resected specimens or clinical outcomes during surveillance after PLC-CB. Results Histocytological evaluations using PLC-CB were performed in 87.8% (36/41) of the patients. For 31 of the 36 patients, final diagnoses (invasive PDAC, 12; pancreatic carcinoma in situ, 5; benignancy, 14) were made, and the remaining five patients were excluded due to lack of surveillance periods after PLC-CB. For 31 patients, the sensitivity, specificity, and accuracy of PLC-CB for detecting malignancy were 94.1%, 100%, and 96.8%, respectively. In addition, they were 87.5%, 100%, and 94.1%, respectively, in 17 patients without pancreatic masses detectable using endoscopic ultrasonography. Four patients developed postprocedural pancreatitis, which improved with conservative therapy. Conclusions PLC-CB has an excellent ability to detect malignancies in patients with possible PDACs, including pancreatic carcinoma in situ.

Keywords